(2017). XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America. test, 1(1), -. doi: 10.21608/cvrepj.2017.352431
. "XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America". test, 1, 1, 2017, -. doi: 10.21608/cvrepj.2017.352431
(2017). 'XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America', test, 1(1), pp. -. doi: 10.21608/cvrepj.2017.352431
XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America. test, 2017; 1(1): -. doi: 10.21608/cvrepj.2017.352431

XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America

Cardiovascular Research Prove Journal
Volume 1, Issue 1, 2017    PDF (252.43 K)
Document Type: Abstracts
DOI: 10.21608/cvrepj.2017.352431
Abstract
The real-world, international, prospective, observational XANTUS study demonstrated low rates of stroke
and major bleeding in an unselected atrial fibrillation (AF) patient population treated with rivaroxaban in routine
clinical practice in Europe, Canada and Israel. XANTUS-EL is a sister study to XANTUS with the aim to
investigate the safety and effectiveness of rivaroxaban in routine clinical use in patients with AF in Eastern Europe,
Middle East, Africa and Latin America.
Statistics
Article View: 32
PDF Download: 34